Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour

Completed

• Conditions: Giant Cell Tumors

• Registration Number: NCT05542524
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Giant cell tumors are mostly benign tomoral processes, most often responsible for areas of osteolysis in the metaphysoepiphyseal area of long bones, representing 5-6% of primary bone tumors. The bone weakening induced by these beaches leads to pain and risk of fracture, and this is what leads the patient to consult.

These tumors are found particularly in the young adult population between 20 and 40 years old, are locally aggressive, but malignant transformations and metastases (pulmonary) are quite rare.

In this study, the investigators wish to retrospectively study the oral care of patients who presented with a giant cell tumor and were treated with Denosumab at the University Hospital of Strasbourg and their associated oral follow-up

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-01
• Study First Submitted: 2022-09-12
• Study First Submitted QC: 2022-09-12
• Study First Posted: 2022-09-15
• Primary Completion: 2023-06-30
• Study Completion: 2023-08-31
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-12
• Last Update Posted: 2023-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of Decayed, Missing, and Filled Permanent Teeth (DMFT)	Files analysed retrospectively from from January 01, 2014 to August 31, 2022 will be examined

Trial Locations

Locations (1)

Service de Médecine et Chirurgie Bucco-Dentaires - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France